Condition
FOP
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Garetosmab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 3 (1)
Trial Status
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07559513Phase 3Not Yet Recruiting
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
NCT04829786Phase 1CompletedPrimary
Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects
Showing all 2 trials
Research Network
Common Treatments
- Garetosmab1
- Palovarotene1
Active Sponsors
- Regeneron Pharmaceuticals, Inc.1
- Clementia Pharmaceuticals Inc.1
Related Conditions
- Fibrodysplasia Ossificans Progressiva1